Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 1
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer.
Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT. Wang X, et al. Sci Adv. 2022 Dec 16;8(50):eabn7983. doi: 10.1126/sciadv.abn7983. Epub 2022 Dec 16. Sci Adv. 2022. PMID: 36525493 Free PMC article.
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Masuda H, et al. JCO Precis Oncol. 2022 Mar;6:e2000368. doi: 10.1200/PO.20.00368. JCO Precis Oncol. 2022. PMID: 35294223 Free PMC article.
Targeting Signaling Pathways in Inflammatory Breast Cancer.
Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, Lim B, Ueno NT. Wang X, et al. Cancers (Basel). 2020 Sep 1;12(9):2479. doi: 10.3390/cancers12092479. Cancers (Basel). 2020. PMID: 32883032 Free PMC article. Review.
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.
Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Matsuda N, et al. JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436. JAMA Oncol. 2018. PMID: 29879283 Free PMC article. Clinical Trial.
EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.
Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA Jr, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. Wang X, et al. Oncotarget. 2017 Jul 4;8(40):67904-67917. doi: 10.18632/oncotarget.18958. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978083 Free PMC article.